Basic HTML Version
MEDICAL
maintain an ambitious investment policy. In 2011, 5.3% of LISI
MEDICAL Orthopaedics’ sales revenues were spent on developing
the “reconstruction” activity. The objective is to broaden the
range of products to all segments of reconstructive surgery
(reconstruction of knees, shoulders and implant instruments).
These capital expenditures have helped to internalize processes
that were previously outsourced. LISI MEDICAL Orthopaedics has
invested in latest generation machining centers that guarantee the
technological progression of the various standalone production
units (or manufacturing islets). Productivity gains are also expected
to maintain the site’s competitiveness with the automation of
certain manufacturing stages (shaping and polishing for instance).
The mastery of processes was also strengthened through the
acquisition of image-based control means. The machine capacity
for packaging in a controlled environment has also been increased.
Efforts to expand the reconstruction segment’s offer were
accompanied by the creation of a “projects and sales” structure,
which should allow to accelerate the division’s commercial
development. The teamwill ensure the continuity of the
relationship with the Stryker group, while developing new
customers. This differentiation strategy has allowed the division
to strengthen its partnerships with key players in the international
market where it displays a comprehensive, consistent offer.
A new building
in Morocco
LISI MEDICAL acquires the necessary
infrastructure to support its growth and
offer its customers a competitive offering
for emerging markets.The commissioning
of a new 5,000 square meters site in
the Tangier Free Zone, was scheduled
in 2011. The building, which will also
host a manufacturing workshop for LISI
AEROSPACE using the same technologies,
paves the way for new synergies between
divisions.
300,000
LISI MEDICAL Orthopaedics in Caen forges
more than 300,000 hip stems peryear